Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) EBIT Margin (2023 - 2025)

Mangoceuticals' EBIT Margin history spans 3 years, with the latest figure at 389.72% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 463289.0% to 389.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 3954.28%, a 365738.0% decrease, with the full-year FY2025 number at 3954.28%, down 365738.0% from a year prior.
  • EBIT Margin hit 389.72% in Q4 2025 for Mangoceuticals, up from 8953.45% in the prior quarter.
  • Over the last five years, EBIT Margin for MGRX hit a ceiling of 4243.18% in Q4 2024 and a floor of 8953.45% in Q3 2025.
  • Historically, EBIT Margin has averaged 1864.65% across 3 years, with a median of 1323.67% in 2024.
  • Biggest five-year swings in EBIT Margin: surged 529404bps in 2024 and later tumbled -763524bps in 2025.
  • Tracing MGRX's EBIT Margin over 3 years: stood at 1050.87% in 2023, then skyrocketed by 504bps to 4243.18% in 2024, then plummeted by -109bps to 389.72% in 2025.
  • Business Quant data shows EBIT Margin for MGRX at 389.72% in Q4 2025, 8953.45% in Q3 2025, and 3133.98% in Q2 2025.